Citigroup issued a buy rating and price target for Neurocrine Biosciences, with MarketBeat reporting stock average rating.
1 report, 1 independent
Updated Jul 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup issued a buy rating and price target for Neurocrine Biosciences, with MarketBeat reporting stock average rating.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
-
Neurocrine Biosciences
American biopharmaceutical company
Nothing else this week.
-
MarketBeat
American personal finance blog
Related events
- Citigroup boosted its price target and gave a buy rating for Wholesale Club, with MarketBeat providing consensus data.
- Citigroup lifted its price target and gave a buy rating for Timken Company, with MarketBeat providing consensus data.
- Citigroup restated a buy rating on shares of Intensity Therapeutics.
- Citigroup reiterated a market perform rating for Inhibrx Biosciences.
- Benchmark initiated coverage with a buy rating, while MarketBeat provided consensus data and Citigroup reduced its target price.